Kamada Ltd. Net Income 2011-2025 | KMDA

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Kamada Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-2.23 M	17.1 M	22.3 M	22.3 M	6.9 M	-6.73 M	-11.3 M	-13.2 M	400 K	260 K	-3.49 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22.3 M	-13.2 M	2.94 M

Quarterly Net Income Kamada Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-845 K	-	-	-	6.84 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.84 M	-845 K	3 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	-83.7 M	-	1052.0 %	$ 415 M	USA
Amphastar Pharmaceuticals AMPH	160 M	$ 25.27	-2.43 %	$ 1.22 B	USA
MorphoSys AG MOR	-514 M	-	2.43 %	$ 254 M	Germany
Alpine Immune Sciences ALPN	-57.8 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	-72.8 M	$ 4.75	1.61 %	$ 788 M	Canada
Aclaris Therapeutics ACRS	-132 M	$ 3.26	-3.12 %	$ 252 M	USA
AlloVir ALVR	-58.8 M	-	4.14 %	$ 49.1 M	USA
Acasti Pharma ACST	-9.57 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-114 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	-8.63 M	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	-208 M	-	-	$ 1.01 B	USA
Alexion Pharmaceuticals, Inc. ALXN	603 M	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	-384 M	$ 220.27	4.81 %	$ 5 B	Danmark
Albireo Pharma ALBO	-34 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	-38 M	-	-	$ 7.46 M	Israel
Enlivex Therapeutics Ltd. ENLV	-15 M	$ 0.91	-5.01 %	$ 18.7 M	Israel
Can-Fite BioPharma Ltd. CANF	-7.88 M	$ 0.28	-2.28 %	$ 609 M	Israel
Alterity Therapeutics Limited ATHE	-12.8 M	$ 3.3	-3.51 %	$ 7.94 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	-8.09 M	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	115 M	$ 89.78	-0.57 %	$ 96.9 B	Britain
Midatech Pharma plc MTP	-5.46 M	-	-18.52 %	$ 27.3 M	Britain
Anika Therapeutics ANIK	-82.7 M	$ 9.57	0.84 %	$ 140 M	USA
Brickell Biotech BBI	-5.69 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	-645 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	-25 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-98 M	-	-7.31 %	$ 87 M	USA
Benitec Biopharma BNTC	-8.8 M	$ 12.05	-7.06 %	$ 496 M	USA
Aytu BioScience AYTU	-13.6 M	$ 2.34	2.59 %	$ 14.7 M	USA
Nymox Pharmaceutical Corporation NYMX	-12.5 M	-	-19.68 %	$ 18.4 M	Canada
Arena Pharmaceuticals ARNA	-616 M	-	-6.81 %	$ 3.04 B	USA
Aptorum Group Limited APM	-4.27 M	$ 1.29	-3.01 %	$ 7.03 M	China
Biophytis SA BPTS	-31.2 M	-	-13.47 %	$ 169 M	France
Baudax Bio BXRX	-58.8 M	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	-11.7 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Catalyst Biosciences CBIO	-85.5 M	$ 14.01	-8.49 %	$ 922 M	USA
ChromaDex Corporation CDXC	8.55 M	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	377 M	$ 566.18	-2.56 %	$ 42.9 B	USA
Cerus Corporation CERS	-20.9 M	$ 2.16	0.47 %	$ 399 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	-20 M	-	-16.75 %	$ 25.8 M	USA
Clovis Oncology CLVS	-265 M	-	-7.23 %	$ 13 M	USA
Biogen BIIB	1.63 B	$ 174.42	1.11 %	$ 25.4 B	USA
BioVie BIVI	-17.5 M	$ 1.42	-5.96 %	$ 2.1 M	USA
Celldex Therapeutics CLDX	-158 M	$ 27.36	-2.09 %	$ 1.76 M	USA
Cortexyme CRTX	-31.4 M	-	-1.05 %	$ 67.1 M	USA
Cellectar Biosciences CLRB	-42.8 M	$ 3.63	-3.97 %	$ 44.4 M	USA
Deciphera Pharmaceuticals DCPH	-195 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-847 M	$ 11.54	0.87 %	$ 746 M	USA